NCT01366612: A trial that was reported late by Hackensack Meridian Health
This trial has reported, although it was 458 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT01366612 |
|---|---|
| Title | PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | June 16, 2010 |
| Completion date | Aug. 17, 2020 |
| Required reporting date | Aug. 17, 2021, midnight |
| Actual reporting date | Nov. 18, 2022 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 458 |